nodes	percent_of_prediction	percent_of_DWPC	metapath
Varenicline—CHRNA3—lung cancer	0.629	1	CbGaD
Varenicline—CHRNA6—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00254	0.0141	CbGpPWpGaD
Varenicline—CHRNA4—Highly sodium permeable acetylcholine nicotinic receptors—CHRNB4—lung cancer	0.00252	0.0141	CbGpPWpGaD
Varenicline—CHRNA3—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.00248	0.0138	CbGpPWpGaD
Varenicline—CHRNB2—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.00242	0.0135	CbGpPWpGaD
Varenicline—CHRNB2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00239	0.0133	CbGpPWpGaD
Varenicline—CHRNA3—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.00227	0.0127	CbGpPWpGaD
Varenicline—CHRNA6—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00224	0.0125	CbGpPWpGaD
Varenicline—CHRNB2—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00223	0.0124	CbGpPWpGaD
Varenicline—CHRNA7—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.00216	0.012	CbGpPWpGaD
Varenicline—CHRNA3—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.00212	0.0118	CbGpPWpGaD
Varenicline—CHRNA3—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.00211	0.0118	CbGpPWpGaD
Varenicline—CHRNA4—Highly calcium permeable nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.00207	0.0115	CbGpPWpGaD
Varenicline—CHRNA7—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.00201	0.0112	CbGpPWpGaD
Varenicline—CHRNA6—Nicotine Activity on Dopaminergic Neurons—CHRNA5—lung cancer	0.00199	0.0111	CbGpPWpGaD
Varenicline—CHRNB2—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00197	0.011	CbGpPWpGaD
Varenicline—CHRNA3—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.00197	0.011	CbGpPWpGaD
Varenicline—CHRNA4—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.00192	0.0107	CbGpPWpGaD
Varenicline—CHRNA4—Highly sodium permeable acetylcholine nicotinic receptors—CHRNA3—lung cancer	0.00191	0.0106	CbGpPWpGaD
Varenicline—CHRNA3—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.00187	0.0104	CbGpPWpGaD
Varenicline—CHRNA7—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.00178	0.0099	CbGpPWpGaD
Varenicline—CHRNA4—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.00176	0.00979	CbGpPWpGaD
Varenicline—CHRNB2—Nicotine Activity on Dopaminergic Neurons—CHRNA5—lung cancer	0.00175	0.00974	CbGpPWpGaD
Varenicline—CHRNA3—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.00174	0.0097	CbGpPWpGaD
Varenicline—CHRNA7—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.00165	0.0092	CbGpPWpGaD
Varenicline—CHRNA4—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.00164	0.00913	CbGpPWpGaD
Varenicline—CHRNA4—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.00164	0.0091	CbGpPWpGaD
Varenicline—CHRNA7—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00164	0.0091	CbGpPWpGaD
Varenicline—CHRNA6—Nicotine Activity on Dopaminergic Neurons—CHRNA3—lung cancer	0.00162	0.00902	CbGpPWpGaD
Varenicline—CHRNA4—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00157	0.00871	CbGpPWpGaD
Varenicline—CHRNA4—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.00153	0.00849	CbGpPWpGaD
Varenicline—CHRNA4—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.00145	0.00807	CbGpPWpGaD
Varenicline—CHRNB2—Nicotine Activity on Dopaminergic Neurons—CHRNA3—lung cancer	0.00143	0.00794	CbGpPWpGaD
Varenicline—CHRNA7—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00135	0.0075	CbGpPWpGaD
Varenicline—CHRNA4—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.00135	0.0075	CbGpPWpGaD
Varenicline—CHRNA4—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00133	0.00742	CbGpPWpGaD
Varenicline—CHRNA3—Nicotine Activity on Dopaminergic Neurons—CHRNA5—lung cancer	0.00126	0.00701	CbGpPWpGaD
Varenicline—CHRNA4—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00124	0.00692	CbGpPWpGaD
Varenicline—CHRNA3—respiratory system—lung cancer	0.00115	0.126	CbGeAlD
Varenicline—CHRNA4—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.0011	0.00612	CbGpPWpGaD
Varenicline—CHRNB2—bronchus—lung cancer	0.000978	0.107	CbGeAlD
Varenicline—CHRNA4—Nicotine Activity on Dopaminergic Neurons—CHRNA5—lung cancer	0.000975	0.00542	CbGpPWpGaD
Varenicline—CHRFAM7A—respiratory system—lung cancer	0.000932	0.102	CbGeAlD
Varenicline—CHRNB2—trachea—lung cancer	0.000878	0.0958	CbGeAlD
Varenicline—CHRNA4—Nicotine Activity on Dopaminergic Neurons—CHRNA3—lung cancer	0.000795	0.00442	CbGpPWpGaD
Varenicline—CHRNA4—respiratory system—lung cancer	0.000743	0.081	CbGeAlD
Varenicline—CHRNB2—bone marrow—lung cancer	0.000697	0.076	CbGeAlD
Varenicline—CHRFAM7A—trachea—lung cancer	0.000689	0.0752	CbGeAlD
Varenicline—CHRNB2—lung—lung cancer	0.000631	0.0688	CbGeAlD
Varenicline—CHRNA3—lung—lung cancer	0.000612	0.0668	CbGeAlD
Varenicline—CHRNA4—bronchus—lung cancer	0.000611	0.0667	CbGeAlD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.000575	0.0032	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.000506	0.00282	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.000469	0.00261	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.000436	0.00242	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—GRIK3—lung cancer	0.000432	0.00241	CbGpPWpGaD
Varenicline—CHRNB2—lymph node—lung cancer	0.000432	0.0471	CbGeAlD
Varenicline—CHRNA3—lymph node—lung cancer	0.000419	0.0457	CbGeAlD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.000413	0.0023	CbGpPWpGaD
Varenicline—CHRNA4—lung—lung cancer	0.000394	0.043	CbGeAlD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.000384	0.00213	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—GRIK3—lung cancer	0.000381	0.00212	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—KMT2A—lung cancer	0.000379	0.00211	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CHRNB4—lung cancer	0.000378	0.00211	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.000364	0.00203	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.000355	0.00198	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.000352	0.00196	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TOP1—lung cancer	0.000347	0.00193	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.000346	0.00192	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—NKX2-1—lung cancer	0.000338	0.00188	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.000336	0.00187	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—GRIK3—lung cancer	0.000331	0.00184	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.000328	0.00182	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.000313	0.00174	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.00031	0.00173	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.000302	0.00168	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.000297	0.00165	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.000296	0.00165	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—GRIK3—lung cancer	0.000292	0.00162	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.000288	0.0016	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—FOXM1—lung cancer	0.000287	0.0016	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.000282	0.00157	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.000282	0.00157	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.000276	0.00154	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—GRIK3—lung cancer	0.000274	0.00152	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—CHRNB4—lung cancer	0.00027	0.0015	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.000267	0.00149	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—SOX2—lung cancer	0.000267	0.00148	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.000266	0.00148	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.000262	0.00146	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—GRIK3—lung cancer	0.00026	0.00145	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CHRNB4—lung cancer	0.000259	0.00144	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—ALDOA—lung cancer	0.000258	0.00144	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—GNG11—lung cancer	0.000253	0.00141	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—CHRNA5—lung cancer	0.000251	0.0014	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—CHRNB4—lung cancer	0.000238	0.00132	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.000235	0.00131	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.00023	0.00128	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000227	0.00126	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—TF—lung cancer	0.000227	0.00126	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—AHR—lung cancer	0.000223	0.00124	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.000223	0.00124	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—GNG11—lung cancer	0.000222	0.00124	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—CHRNA5—lung cancer	0.000221	0.00123	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.000214	0.00119	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.000214	0.00119	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.000213	0.00118	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—GRIK3—lung cancer	0.000212	0.00118	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.000212	0.00118	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CHRNB4—lung cancer	0.000211	0.00117	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—GRIK3—lung cancer	0.00021	0.00117	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.000208	0.00116	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—CHRNA3—lung cancer	0.000205	0.00114	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.000202	0.00112	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—ADCY1—lung cancer	0.0002	0.00111	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—GRIK3—lung cancer	0.000199	0.00111	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—ADCY1—lung cancer	0.000199	0.00111	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.000197	0.0011	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—FOXM1—lung cancer	0.000196	0.00109	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—GNG11—lung cancer	0.000193	0.00108	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.000191	0.00107	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—SOX2—lung cancer	0.000182	0.00101	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.000182	0.00101	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—CHRNA3—lung cancer	0.00018	0.001	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—ALDOA—lung cancer	0.000176	0.000982	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.000174	0.000969	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—ADCY1—lung cancer	0.000174	0.000968	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.000173	0.000962	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—CHRNB4—lung cancer	0.000171	0.000952	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—GNG11—lung cancer	0.00017	0.000948	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.000165	0.000917	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—GRIK3—lung cancer	0.000162	0.000904	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—CHRNB4—lung cancer	0.000162	0.000904	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.000161	0.000894	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.000161	0.000894	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—GNG11—lung cancer	0.00016	0.000891	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—FOXM1—lung cancer	0.00016	0.000889	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—CHRNA5—lung cancer	0.000159	0.000885	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—AVP—lung cancer	0.000157	0.000874	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—TF—lung cancer	0.000155	0.000862	CbGpPWpGaD
Varenicline—CHRNB2—Neuronal System—ADCY1—lung cancer	0.000153	0.000852	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—GNG11—lung cancer	0.000152	0.000845	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—CHRNA5—lung cancer	0.000151	0.00084	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HES1—lung cancer	0.000149	0.000827	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—SOX2—lung cancer	0.000149	0.000826	CbGpPWpGaD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.000148	0.000824	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL10—lung cancer	0.000148	0.000822	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000144	0.000801	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—ALDOA—lung cancer	0.000144	0.0008	CbGpPWpGaD
Varenicline—CHRNA7—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000137	0.00076	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—CHRNB4—lung cancer	0.000132	0.000737	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.000131	0.000729	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—AVP—lung cancer	0.000128	0.000714	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000128	0.000711	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—TF—lung cancer	0.000126	0.000703	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—HIF1A—lung cancer	0.000125	0.000693	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—GNG11—lung cancer	0.000124	0.000689	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—CHRNA5—lung cancer	0.000123	0.000685	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—CHRNA3—lung cancer	0.000123	0.000685	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—GNG11—lung cancer	0.000123	0.000683	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—TYMS—lung cancer	0.000122	0.000679	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—GNG11—lung cancer	0.000116	0.000648	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000112	0.000626	CbGpPWpGaD
Varenicline—CHRNA4—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000111	0.00062	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—ADCY1—lung cancer	0.00011	0.000614	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—AVP—lung cancer	0.000107	0.000598	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	0.000107	0.000595	CbGpPWpGaD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	0.000107	0.000593	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—ADCY1—lung cancer	0.000105	0.000582	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL6R—lung cancer	0.000102	0.000567	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CREBBP—lung cancer	0.000102	0.000566	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HES1—lung cancer	0.000102	0.000565	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL10—lung cancer	0.000101	0.000562	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—CHRNA3—lung cancer	0.0001	0.000558	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—BRAF—lung cancer	9.6e-05	0.000534	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—GNG11—lung cancer	9.49e-05	0.000528	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	9.42e-05	0.000524	CbGpPWpGaD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	9.39e-05	0.000522	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—AVP—lung cancer	8.75e-05	0.000487	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—ADCY1—lung cancer	8.53e-05	0.000475	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—HIF1A—lung cancer	8.51e-05	0.000473	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—BRAF—lung cancer	8.45e-05	0.00047	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HES1—lung cancer	8.28e-05	0.000461	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL10—lung cancer	8.23e-05	0.000458	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	8.1e-05	0.000451	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CXCL8—lung cancer	8.08e-05	0.00045	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—MDM2—lung cancer	8.04e-05	0.000448	CbGpPWpGaD
Varenicline—CHRNA6—Transmission across Chemical Synapses—RAF1—lung cancer	8.02e-05	0.000446	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—CASP3—lung cancer	7.73e-05	0.00043	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	7.68e-05	0.000428	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—JUN—lung cancer	7.51e-05	0.000418	CbGpPWpGaD
Varenicline—CHRNA6—Neuronal System—BRAF—lung cancer	7.36e-05	0.000409	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—MDM2—lung cancer	7.08e-05	0.000394	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—RAF1—lung cancer	7.06e-05	0.000393	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL6R—lung cancer	6.96e-05	0.000387	CbGpPWpGaD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CREBBP—lung cancer	6.95e-05	0.000387	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—HIF1A—lung cancer	6.94e-05	0.000386	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—EP300—lung cancer	6.93e-05	0.000385	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	6.78e-05	0.000378	CbGpPWpGaD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	6.76e-05	0.000376	CbGpPWpGaD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—VEGFA—lung cancer	6.56e-05	0.000365	CbGpPWpGaD
Varenicline—Chest pain—Docetaxel—lung cancer	6.55e-05	0.000359	CcSEcCtD
Varenicline—Myalgia—Docetaxel—lung cancer	6.55e-05	0.000359	CcSEcCtD
Varenicline—Nausea—Vinorelbine—lung cancer	6.55e-05	0.000359	CcSEcCtD
Varenicline—Gastrointestinal disorder—Etoposide—lung cancer	6.53e-05	0.000358	CcSEcCtD
Varenicline—Dyspepsia—Paclitaxel—lung cancer	6.52e-05	0.000358	CcSEcCtD
Varenicline—Body temperature increased—Cisplatin—lung cancer	6.52e-05	0.000358	CcSEcCtD
Varenicline—Asthenia—Irinotecan—lung cancer	6.52e-05	0.000357	CcSEcCtD
Varenicline—Fatigue—Etoposide—lung cancer	6.52e-05	0.000357	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	6.51e-05	0.000357	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—BRAF—lung cancer	6.48e-05	0.00036	CbGpPWpGaD
Varenicline—Constipation—Etoposide—lung cancer	6.46e-05	0.000354	CcSEcCtD
Varenicline—Pain—Etoposide—lung cancer	6.46e-05	0.000354	CcSEcCtD
Varenicline—Decreased appetite—Paclitaxel—lung cancer	6.44e-05	0.000353	CcSEcCtD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	6.44e-05	0.000358	CbGpPWpGaD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	6.41e-05	0.000357	CbGpPWpGaD
Varenicline—Dry mouth—Docetaxel—lung cancer	6.41e-05	0.000351	CcSEcCtD
Varenicline—Gastrointestinal disorder—Paclitaxel—lung cancer	6.4e-05	0.000351	CcSEcCtD
Varenicline—Fatigue—Paclitaxel—lung cancer	6.39e-05	0.00035	CcSEcCtD
Varenicline—Pollakiuria—Doxorubicin—lung cancer	6.37e-05	0.000349	CcSEcCtD
Varenicline—Asthenia—Gemcitabine—lung cancer	6.35e-05	0.000348	CcSEcCtD
Varenicline—Pain—Paclitaxel—lung cancer	6.34e-05	0.000348	CcSEcCtD
Varenicline—Constipation—Paclitaxel—lung cancer	6.34e-05	0.000348	CcSEcCtD
Varenicline—Urinary tract disorder—Methotrexate—lung cancer	6.29e-05	0.000345	CcSEcCtD
Varenicline—Photosensitivity reaction—Doxorubicin—lung cancer	6.29e-05	0.000345	CcSEcCtD
Varenicline—Oedema—Docetaxel—lung cancer	6.28e-05	0.000344	CcSEcCtD
Varenicline—Weight increased—Doxorubicin—lung cancer	6.27e-05	0.000344	CcSEcCtD
Varenicline—Pruritus—Gemcitabine—lung cancer	6.26e-05	0.000343	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	6.26e-05	0.000349	CbGpPWpGaD
Varenicline—Urethral disorder—Methotrexate—lung cancer	6.25e-05	0.000343	CcSEcCtD
Varenicline—Infection—Docetaxel—lung cancer	6.24e-05	0.000342	CcSEcCtD
Varenicline—Feeling abnormal—Etoposide—lung cancer	6.23e-05	0.000342	CcSEcCtD
Varenicline—Hyperglycaemia—Doxorubicin—lung cancer	6.22e-05	0.000341	CcSEcCtD
Varenicline—Diarrhoea—Irinotecan—lung cancer	6.22e-05	0.000341	CcSEcCtD
Varenicline—Gastrointestinal pain—Etoposide—lung cancer	6.18e-05	0.000339	CcSEcCtD
Varenicline—Shock—Docetaxel—lung cancer	6.18e-05	0.000339	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—MDM2—lung cancer	6.16e-05	0.000343	CbGpPWpGaD
Varenicline—Nervous system disorder—Docetaxel—lung cancer	6.16e-05	0.000338	CcSEcCtD
Varenicline—Thrombocytopenia—Docetaxel—lung cancer	6.15e-05	0.000337	CcSEcCtD
Varenicline—Infestation NOS—Doxorubicin—lung cancer	6.15e-05	0.000337	CcSEcCtD
Varenicline—Infestation—Doxorubicin—lung cancer	6.15e-05	0.000337	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—RAF1—lung cancer	6.14e-05	0.000342	CbGpPWpGaD
Varenicline—Visual impairment—Methotrexate—lung cancer	6.14e-05	0.000337	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—JUN—lung cancer	6.13e-05	0.000341	CbGpPWpGaD
Varenicline—Tachycardia—Docetaxel—lung cancer	6.13e-05	0.000336	CcSEcCtD
Varenicline—Feeling abnormal—Paclitaxel—lung cancer	6.11e-05	0.000335	CcSEcCtD
Varenicline—Skin disorder—Docetaxel—lung cancer	6.1e-05	0.000335	CcSEcCtD
Varenicline—Stevens-Johnson syndrome—Doxorubicin—lung cancer	6.09e-05	0.000334	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—BRAF—lung cancer	6.09e-05	0.000339	CbGpPWpGaD
Varenicline—Hypersensitivity—Cisplatin—lung cancer	6.08e-05	0.000333	CcSEcCtD
Varenicline—Gastrointestinal pain—Paclitaxel—lung cancer	6.06e-05	0.000332	CcSEcCtD
Varenicline—Diarrhoea—Gemcitabine—lung cancer	6.06e-05	0.000332	CcSEcCtD
Varenicline—Erythema multiforme—Methotrexate—lung cancer	6.03e-05	0.00033	CcSEcCtD
Varenicline—Dizziness—Irinotecan—lung cancer	6.01e-05	0.000329	CcSEcCtD
Varenicline—Urticaria—Etoposide—lung cancer	6.01e-05	0.000329	CcSEcCtD
Varenicline—Stomatitis—Doxorubicin—lung cancer	5.99e-05	0.000329	CcSEcCtD
Varenicline—Anorexia—Docetaxel—lung cancer	5.99e-05	0.000328	CcSEcCtD
Varenicline—Body temperature increased—Etoposide—lung cancer	5.98e-05	0.000328	CcSEcCtD
Varenicline—Abdominal pain—Etoposide—lung cancer	5.98e-05	0.000328	CcSEcCtD
Varenicline—Conjunctivitis—Doxorubicin—lung cancer	5.98e-05	0.000328	CcSEcCtD
Varenicline—Eye disorder—Methotrexate—lung cancer	5.96e-05	0.000327	CcSEcCtD
Varenicline—Tinnitus—Methotrexate—lung cancer	5.94e-05	0.000326	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—PTEN—lung cancer	5.93e-05	0.00033	CbGpPWpGaD
Varenicline—Asthenia—Cisplatin—lung cancer	5.92e-05	0.000325	CcSEcCtD
Varenicline—Cardiac disorder—Methotrexate—lung cancer	5.91e-05	0.000324	CcSEcCtD
Varenicline—Urticaria—Paclitaxel—lung cancer	5.89e-05	0.000323	CcSEcCtD
Varenicline—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	5.87e-05	0.000327	CbGpPWpGaD
Varenicline—Hypotension—Docetaxel—lung cancer	5.87e-05	0.000322	CcSEcCtD
Varenicline—Abdominal pain—Paclitaxel—lung cancer	5.86e-05	0.000321	CcSEcCtD
Varenicline—Body temperature increased—Paclitaxel—lung cancer	5.86e-05	0.000321	CcSEcCtD
Varenicline—Hepatobiliary disease—Doxorubicin—lung cancer	5.81e-05	0.000319	CcSEcCtD
Varenicline—Epistaxis—Doxorubicin—lung cancer	5.8e-05	0.000318	CcSEcCtD
Varenicline—Angiopathy—Methotrexate—lung cancer	5.78e-05	0.000317	CcSEcCtD
Varenicline—Vomiting—Irinotecan—lung cancer	5.78e-05	0.000317	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—BRAF—lung cancer	5.78e-05	0.000321	CbGpPWpGaD
Varenicline—Sinusitis—Doxorubicin—lung cancer	5.77e-05	0.000316	CcSEcCtD
Varenicline—Immune system disorder—Methotrexate—lung cancer	5.76e-05	0.000316	CcSEcCtD
Varenicline—Mediastinal disorder—Methotrexate—lung cancer	5.74e-05	0.000315	CcSEcCtD
Varenicline—Rash—Irinotecan—lung cancer	5.73e-05	0.000314	CcSEcCtD
Varenicline—Dermatitis—Irinotecan—lung cancer	5.72e-05	0.000314	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Docetaxel—lung cancer	5.72e-05	0.000314	CcSEcCtD
Varenicline—Chills—Methotrexate—lung cancer	5.72e-05	0.000314	CcSEcCtD
Varenicline—Headache—Irinotecan—lung cancer	5.69e-05	0.000312	CcSEcCtD
Varenicline—Insomnia—Docetaxel—lung cancer	5.68e-05	0.000312	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL6R—lung cancer	5.67e-05	0.000316	CbGpPWpGaD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CREBBP—lung cancer	5.67e-05	0.000315	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—EP300—lung cancer	5.66e-05	0.000315	CbGpPWpGaD
Varenicline—Diarrhoea—Cisplatin—lung cancer	5.65e-05	0.00031	CcSEcCtD
Varenicline—Vomiting—Gemcitabine—lung cancer	5.63e-05	0.000309	CcSEcCtD
Varenicline—Bradycardia—Doxorubicin—lung cancer	5.62e-05	0.000308	CcSEcCtD
Varenicline—Dyspnoea—Docetaxel—lung cancer	5.6e-05	0.000307	CcSEcCtD
Varenicline—Somnolence—Docetaxel—lung cancer	5.58e-05	0.000306	CcSEcCtD
Varenicline—Mental disorder—Methotrexate—lung cancer	5.58e-05	0.000306	CcSEcCtD
Varenicline—Rash—Gemcitabine—lung cancer	5.58e-05	0.000306	CcSEcCtD
Varenicline—Dermatitis—Gemcitabine—lung cancer	5.58e-05	0.000306	CcSEcCtD
Varenicline—Hypersensitivity—Etoposide—lung cancer	5.57e-05	0.000305	CcSEcCtD
Varenicline—Malnutrition—Methotrexate—lung cancer	5.55e-05	0.000304	CcSEcCtD
Varenicline—Erythema—Methotrexate—lung cancer	5.55e-05	0.000304	CcSEcCtD
Varenicline—Headache—Gemcitabine—lung cancer	5.55e-05	0.000304	CcSEcCtD
Varenicline—Dyspepsia—Docetaxel—lung cancer	5.53e-05	0.000303	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CXCL8—lung cancer	5.52e-05	0.000307	CbGpPWpGaD
Varenicline—Hypoaesthesia—Doxorubicin—lung cancer	5.49e-05	0.000301	CcSEcCtD
Varenicline—Decreased appetite—Docetaxel—lung cancer	5.46e-05	0.000299	CcSEcCtD
Varenicline—Hypersensitivity—Paclitaxel—lung cancer	5.46e-05	0.000299	CcSEcCtD
Varenicline—Urinary tract disorder—Doxorubicin—lung cancer	5.45e-05	0.000299	CcSEcCtD
Varenicline—Oedema peripheral—Doxorubicin—lung cancer	5.44e-05	0.000298	CcSEcCtD
Varenicline—Dysgeusia—Methotrexate—lung cancer	5.43e-05	0.000298	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—MDM2—lung cancer	5.43e-05	0.000302	CbGpPWpGaD
Varenicline—Gastrointestinal disorder—Docetaxel—lung cancer	5.42e-05	0.000297	CcSEcCtD
Varenicline—Asthenia—Etoposide—lung cancer	5.42e-05	0.000297	CcSEcCtD
Varenicline—Connective tissue disorder—Doxorubicin—lung cancer	5.42e-05	0.000297	CcSEcCtD
Varenicline—Fatigue—Docetaxel—lung cancer	5.42e-05	0.000297	CcSEcCtD
Varenicline—Urethral disorder—Doxorubicin—lung cancer	5.41e-05	0.000297	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—RAF1—lung cancer	5.41e-05	0.000301	CbGpPWpGaD
Varenicline—Nausea—Irinotecan—lung cancer	5.4e-05	0.000296	CcSEcCtD
Varenicline—Pain—Docetaxel—lung cancer	5.37e-05	0.000295	CcSEcCtD
Varenicline—Constipation—Docetaxel—lung cancer	5.37e-05	0.000295	CcSEcCtD
Varenicline—Back pain—Methotrexate—lung cancer	5.37e-05	0.000294	CcSEcCtD
Varenicline—Pruritus—Etoposide—lung cancer	5.35e-05	0.000293	CcSEcCtD
Varenicline—Visual impairment—Doxorubicin—lung cancer	5.32e-05	0.000292	CcSEcCtD
Varenicline—Asthenia—Paclitaxel—lung cancer	5.32e-05	0.000292	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—CASP3—lung cancer	5.28e-05	0.000294	CbGpPWpGaD
Varenicline—Nausea—Gemcitabine—lung cancer	5.26e-05	0.000288	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	5.25e-05	0.000292	CbGpPWpGaD
Varenicline—Vomiting—Cisplatin—lung cancer	5.25e-05	0.000288	CcSEcCtD
Varenicline—Pruritus—Paclitaxel—lung cancer	5.24e-05	0.000288	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	5.23e-05	0.000291	CbGpPWpGaD
Varenicline—Vision blurred—Methotrexate—lung cancer	5.23e-05	0.000287	CcSEcCtD
Varenicline—Erythema multiforme—Doxorubicin—lung cancer	5.22e-05	0.000286	CcSEcCtD
Varenicline—Rash—Cisplatin—lung cancer	5.2e-05	0.000285	CcSEcCtD
Varenicline—Dermatitis—Cisplatin—lung cancer	5.2e-05	0.000285	CcSEcCtD
Varenicline—Feeling abnormal—Docetaxel—lung cancer	5.18e-05	0.000284	CcSEcCtD
Varenicline—Diarrhoea—Etoposide—lung cancer	5.17e-05	0.000284	CcSEcCtD
Varenicline—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	5.17e-05	0.000288	CbGpPWpGaD
Varenicline—Eye disorder—Doxorubicin—lung cancer	5.16e-05	0.000283	CcSEcCtD
Varenicline—Ill-defined disorder—Methotrexate—lung cancer	5.15e-05	0.000282	CcSEcCtD
Varenicline—Tinnitus—Doxorubicin—lung cancer	5.15e-05	0.000282	CcSEcCtD
Varenicline—Gastrointestinal pain—Docetaxel—lung cancer	5.14e-05	0.000282	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—JUN—lung cancer	5.13e-05	0.000286	CbGpPWpGaD
Varenicline—Anaemia—Methotrexate—lung cancer	5.13e-05	0.000281	CcSEcCtD
Varenicline—Cardiac disorder—Doxorubicin—lung cancer	5.12e-05	0.000281	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—MDM2—lung cancer	5.1e-05	0.000284	CbGpPWpGaD
Varenicline—CHRNA3—Transmission across Chemical Synapses—RAF1—lung cancer	5.08e-05	0.000283	CbGpPWpGaD
Varenicline—Diarrhoea—Paclitaxel—lung cancer	5.07e-05	0.000278	CcSEcCtD
Varenicline—Angiopathy—Doxorubicin—lung cancer	5.01e-05	0.000275	CcSEcCtD
Varenicline—Malaise—Methotrexate—lung cancer	5e-05	0.000274	CcSEcCtD
Varenicline—Dizziness—Etoposide—lung cancer	5e-05	0.000274	CcSEcCtD
Varenicline—Immune system disorder—Doxorubicin—lung cancer	4.98e-05	0.000273	CcSEcCtD
Varenicline—Vertigo—Methotrexate—lung cancer	4.98e-05	0.000273	CcSEcCtD
Varenicline—Mediastinal disorder—Doxorubicin—lung cancer	4.97e-05	0.000273	CcSEcCtD
Varenicline—Body temperature increased—Docetaxel—lung cancer	4.97e-05	0.000272	CcSEcCtD
Varenicline—Abdominal pain—Docetaxel—lung cancer	4.97e-05	0.000272	CcSEcCtD
Varenicline—Chills—Doxorubicin—lung cancer	4.95e-05	0.000271	CcSEcCtD
Varenicline—Arrhythmia—Doxorubicin—lung cancer	4.93e-05	0.00027	CcSEcCtD
Varenicline—Dizziness—Paclitaxel—lung cancer	4.9e-05	0.000269	CcSEcCtD
Varenicline—Nausea—Cisplatin—lung cancer	4.9e-05	0.000269	CcSEcCtD
Varenicline—Cough—Methotrexate—lung cancer	4.84e-05	0.000265	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—MDM2—lung cancer	4.84e-05	0.000269	CbGpPWpGaD
Varenicline—Mental disorder—Doxorubicin—lung cancer	4.83e-05	0.000265	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—RAF1—lung cancer	4.82e-05	0.000268	CbGpPWpGaD
Varenicline—Convulsion—Methotrexate—lung cancer	4.81e-05	0.000264	CcSEcCtD
Varenicline—Vomiting—Etoposide—lung cancer	4.81e-05	0.000264	CcSEcCtD
Varenicline—Erythema—Doxorubicin—lung cancer	4.8e-05	0.000263	CcSEcCtD
Varenicline—Malnutrition—Doxorubicin—lung cancer	4.8e-05	0.000263	CcSEcCtD
Varenicline—Rash—Etoposide—lung cancer	4.77e-05	0.000261	CcSEcCtD
Varenicline—Dermatitis—Etoposide—lung cancer	4.76e-05	0.000261	CcSEcCtD
Varenicline—Headache—Etoposide—lung cancer	4.74e-05	0.00026	CcSEcCtD
Varenicline—Flatulence—Doxorubicin—lung cancer	4.73e-05	0.00026	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—EP300—lung cancer	4.73e-05	0.000263	CbGpPWpGaD
Varenicline—Chest pain—Methotrexate—lung cancer	4.72e-05	0.000259	CcSEcCtD
Varenicline—Arthralgia—Methotrexate—lung cancer	4.72e-05	0.000259	CcSEcCtD
Varenicline—Myalgia—Methotrexate—lung cancer	4.72e-05	0.000259	CcSEcCtD
Varenicline—Vomiting—Paclitaxel—lung cancer	4.71e-05	0.000258	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—BRAF—lung cancer	4.71e-05	0.000262	CbGpPWpGaD
Varenicline—Dysgeusia—Doxorubicin—lung cancer	4.7e-05	0.000258	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	4.69e-05	0.000257	CcSEcCtD
Varenicline—Rash—Paclitaxel—lung cancer	4.67e-05	0.000256	CcSEcCtD
Varenicline—Dermatitis—Paclitaxel—lung cancer	4.67e-05	0.000256	CcSEcCtD
Varenicline—Discomfort—Methotrexate—lung cancer	4.67e-05	0.000256	CcSEcCtD
Varenicline—CHRNA3—Neuronal System—BRAF—lung cancer	4.66e-05	0.00026	CbGpPWpGaD
Varenicline—Back pain—Doxorubicin—lung cancer	4.65e-05	0.000255	CcSEcCtD
Varenicline—Headache—Paclitaxel—lung cancer	4.64e-05	0.000255	CcSEcCtD
Varenicline—Hypersensitivity—Docetaxel—lung cancer	4.63e-05	0.000254	CcSEcCtD
Varenicline—Muscle spasms—Doxorubicin—lung cancer	4.62e-05	0.000253	CcSEcCtD
Varenicline—CHRNB2—SIDS Susceptibility Pathways—IL6—lung cancer	4.54e-05	0.000253	CbGpPWpGaD
Varenicline—Vision blurred—Doxorubicin—lung cancer	4.53e-05	0.000248	CcSEcCtD
Varenicline—Asthenia—Docetaxel—lung cancer	4.51e-05	0.000247	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CXCL8—lung cancer	4.5e-05	0.00025	CbGpPWpGaD
Varenicline—Infection—Methotrexate—lung cancer	4.5e-05	0.000247	CcSEcCtD
Varenicline—Nausea—Etoposide—lung cancer	4.49e-05	0.000246	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—VEGFA—lung cancer	4.48e-05	0.000249	CbGpPWpGaD
Varenicline—Ill-defined disorder—Doxorubicin—lung cancer	4.46e-05	0.000244	CcSEcCtD
Varenicline—Pruritus—Docetaxel—lung cancer	4.44e-05	0.000244	CcSEcCtD
Varenicline—Nervous system disorder—Methotrexate—lung cancer	4.44e-05	0.000243	CcSEcCtD
Varenicline—Anaemia—Doxorubicin—lung cancer	4.44e-05	0.000243	CcSEcCtD
Varenicline—Thrombocytopenia—Methotrexate—lung cancer	4.43e-05	0.000243	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—BRAF—lung cancer	4.43e-05	0.000246	CbGpPWpGaD
Varenicline—Agitation—Doxorubicin—lung cancer	4.41e-05	0.000242	CcSEcCtD
Varenicline—CHRNA6—Transmission across Chemical Synapses—HRAS—lung cancer	4.41e-05	0.000246	CbGpPWpGaD
Varenicline—Nausea—Paclitaxel—lung cancer	4.4e-05	0.000241	CcSEcCtD
Varenicline—Skin disorder—Methotrexate—lung cancer	4.4e-05	0.000241	CcSEcCtD
Varenicline—Hyperhidrosis—Methotrexate—lung cancer	4.38e-05	0.00024	CcSEcCtD
Varenicline—Malaise—Doxorubicin—lung cancer	4.33e-05	0.000238	CcSEcCtD
Varenicline—Vertigo—Doxorubicin—lung cancer	4.32e-05	0.000237	CcSEcCtD
Varenicline—Anorexia—Methotrexate—lung cancer	4.32e-05	0.000237	CcSEcCtD
Varenicline—Syncope—Doxorubicin—lung cancer	4.31e-05	0.000236	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—CASP3—lung cancer	4.31e-05	0.00024	CbGpPWpGaD
Varenicline—Diarrhoea—Docetaxel—lung cancer	4.3e-05	0.000236	CcSEcCtD
Varenicline—Palpitations—Doxorubicin—lung cancer	4.25e-05	0.000233	CcSEcCtD
Varenicline—Hypotension—Methotrexate—lung cancer	4.23e-05	0.000232	CcSEcCtD
Varenicline—Loss of consciousness—Doxorubicin—lung cancer	4.22e-05	0.000232	CcSEcCtD
Varenicline—Cough—Doxorubicin—lung cancer	4.19e-05	0.00023	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—JUN—lung cancer	4.18e-05	0.000233	CbGpPWpGaD
Varenicline—Convulsion—Doxorubicin—lung cancer	4.16e-05	0.000228	CcSEcCtD
Varenicline—Dizziness—Docetaxel—lung cancer	4.15e-05	0.000228	CcSEcCtD
Varenicline—Hypertension—Doxorubicin—lung cancer	4.15e-05	0.000227	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Methotrexate—lung cancer	4.13e-05	0.000226	CcSEcCtD
Varenicline—Insomnia—Methotrexate—lung cancer	4.1e-05	0.000225	CcSEcCtD
Varenicline—Myalgia—Doxorubicin—lung cancer	4.09e-05	0.000224	CcSEcCtD
Varenicline—Chest pain—Doxorubicin—lung cancer	4.09e-05	0.000224	CcSEcCtD
Varenicline—Arthralgia—Doxorubicin—lung cancer	4.09e-05	0.000224	CcSEcCtD
Varenicline—Anxiety—Doxorubicin—lung cancer	4.08e-05	0.000223	CcSEcCtD
Varenicline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	4.06e-05	0.000223	CcSEcCtD
Varenicline—CHRNB2—Circadian rythm related genes—TP53—lung cancer	4.05e-05	0.000225	CbGpPWpGaD
Varenicline—Discomfort—Doxorubicin—lung cancer	4.04e-05	0.000222	CcSEcCtD
Varenicline—Dyspnoea—Methotrexate—lung cancer	4.04e-05	0.000221	CcSEcCtD
Varenicline—Somnolence—Methotrexate—lung cancer	4.03e-05	0.000221	CcSEcCtD
Varenicline—Dry mouth—Doxorubicin—lung cancer	4e-05	0.000219	CcSEcCtD
Varenicline—Vomiting—Docetaxel—lung cancer	3.99e-05	0.000219	CcSEcCtD
Varenicline—Dyspepsia—Methotrexate—lung cancer	3.99e-05	0.000219	CcSEcCtD
Varenicline—Rash—Docetaxel—lung cancer	3.96e-05	0.000217	CcSEcCtD
Varenicline—Dermatitis—Docetaxel—lung cancer	3.96e-05	0.000217	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—MDM2—lung cancer	3.94e-05	0.00022	CbGpPWpGaD
Varenicline—Decreased appetite—Methotrexate—lung cancer	3.94e-05	0.000216	CcSEcCtD
Varenicline—Headache—Docetaxel—lung cancer	3.94e-05	0.000216	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—RAF1—lung cancer	3.93e-05	0.000219	CbGpPWpGaD
Varenicline—Oedema—Doxorubicin—lung cancer	3.92e-05	0.000215	CcSEcCtD
Varenicline—Gastrointestinal disorder—Methotrexate—lung cancer	3.91e-05	0.000214	CcSEcCtD
Varenicline—CHRNA3—Neuronal System—MDM2—lung cancer	3.91e-05	0.000217	CbGpPWpGaD
Varenicline—Fatigue—Methotrexate—lung cancer	3.9e-05	0.000214	CcSEcCtD
Varenicline—Infection—Doxorubicin—lung cancer	3.9e-05	0.000214	CcSEcCtD
Varenicline—CHRNA3—Neuronal System—RAF1—lung cancer	3.89e-05	0.000217	CbGpPWpGaD
Varenicline—CHRNB2—Transmission across Chemical Synapses—HRAS—lung cancer	3.89e-05	0.000216	CbGpPWpGaD
Varenicline—Pain—Methotrexate—lung cancer	3.87e-05	0.000212	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—EP300—lung cancer	3.86e-05	0.000215	CbGpPWpGaD
Varenicline—Shock—Doxorubicin—lung cancer	3.86e-05	0.000211	CcSEcCtD
Varenicline—Nervous system disorder—Doxorubicin—lung cancer	3.84e-05	0.000211	CcSEcCtD
Varenicline—Thrombocytopenia—Doxorubicin—lung cancer	3.84e-05	0.00021	CcSEcCtD
Varenicline—Tachycardia—Doxorubicin—lung cancer	3.83e-05	0.00021	CcSEcCtD
Varenicline—Skin disorder—Doxorubicin—lung cancer	3.81e-05	0.000209	CcSEcCtD
Varenicline—Hyperhidrosis—Doxorubicin—lung cancer	3.79e-05	0.000208	CcSEcCtD
Varenicline—Anorexia—Doxorubicin—lung cancer	3.74e-05	0.000205	CcSEcCtD
Varenicline—Nausea—Docetaxel—lung cancer	3.73e-05	0.000205	CcSEcCtD
Varenicline—Feeling abnormal—Methotrexate—lung cancer	3.73e-05	0.000205	CcSEcCtD
Varenicline—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	3.72e-05	0.000207	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—MDM2—lung cancer	3.71e-05	0.000206	CbGpPWpGaD
Varenicline—CHRNB2—Circadian rythm related genes—IL6—lung cancer	3.7e-05	0.000206	CbGpPWpGaD
Varenicline—Gastrointestinal pain—Methotrexate—lung cancer	3.7e-05	0.000203	CcSEcCtD
Varenicline—CHRNA7—Neuronal System—RAF1—lung cancer	3.69e-05	0.000206	CbGpPWpGaD
Varenicline—Hypotension—Doxorubicin—lung cancer	3.66e-05	0.000201	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—VEGFA—lung cancer	3.65e-05	0.000203	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—BRAF—lung cancer	3.61e-05	0.000201	CbGpPWpGaD
Varenicline—Urticaria—Methotrexate—lung cancer	3.6e-05	0.000197	CcSEcCtD
Varenicline—Abdominal pain—Methotrexate—lung cancer	3.58e-05	0.000196	CcSEcCtD
Varenicline—Body temperature increased—Methotrexate—lung cancer	3.58e-05	0.000196	CcSEcCtD
Varenicline—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.57e-05	0.000196	CcSEcCtD
Varenicline—Insomnia—Doxorubicin—lung cancer	3.55e-05	0.000194	CcSEcCtD
Varenicline—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	3.53e-05	0.000197	CbGpPWpGaD
Varenicline—Dyspnoea—Doxorubicin—lung cancer	3.5e-05	0.000192	CcSEcCtD
Varenicline—Somnolence—Doxorubicin—lung cancer	3.49e-05	0.000191	CcSEcCtD
Varenicline—Dyspepsia—Doxorubicin—lung cancer	3.45e-05	0.000189	CcSEcCtD
Varenicline—Decreased appetite—Doxorubicin—lung cancer	3.41e-05	0.000187	CcSEcCtD
Varenicline—Gastrointestinal disorder—Doxorubicin—lung cancer	3.38e-05	0.000186	CcSEcCtD
Varenicline—CHRNA6—Neuronal System—HRAS—lung cancer	3.38e-05	0.000188	CbGpPWpGaD
Varenicline—Fatigue—Doxorubicin—lung cancer	3.38e-05	0.000185	CcSEcCtD
Varenicline—Constipation—Doxorubicin—lung cancer	3.35e-05	0.000184	CcSEcCtD
Varenicline—Pain—Doxorubicin—lung cancer	3.35e-05	0.000184	CcSEcCtD
Varenicline—Hypersensitivity—Methotrexate—lung cancer	3.34e-05	0.000183	CcSEcCtD
Varenicline—Asthenia—Methotrexate—lung cancer	3.25e-05	0.000178	CcSEcCtD
Varenicline—Feeling abnormal—Doxorubicin—lung cancer	3.23e-05	0.000177	CcSEcCtD
Varenicline—Gastrointestinal pain—Doxorubicin—lung cancer	3.21e-05	0.000176	CcSEcCtD
Varenicline—Pruritus—Methotrexate—lung cancer	3.2e-05	0.000176	CcSEcCtD
Varenicline—Urticaria—Doxorubicin—lung cancer	3.11e-05	0.000171	CcSEcCtD
Varenicline—CHRNA7—SIDS Susceptibility Pathways—IL6—lung cancer	3.1e-05	0.000173	CbGpPWpGaD
Varenicline—Abdominal pain—Doxorubicin—lung cancer	3.1e-05	0.00017	CcSEcCtD
Varenicline—Body temperature increased—Doxorubicin—lung cancer	3.1e-05	0.00017	CcSEcCtD
Varenicline—Diarrhoea—Methotrexate—lung cancer	3.1e-05	0.00017	CcSEcCtD
Varenicline—CHRNA4—Neuronal System—MDM2—lung cancer	3.02e-05	0.000168	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—RAF1—lung cancer	3.01e-05	0.000168	CbGpPWpGaD
Varenicline—Dizziness—Methotrexate—lung cancer	2.99e-05	0.000164	CcSEcCtD
Varenicline—CHRNB2—Neuronal System—HRAS—lung cancer	2.98e-05	0.000166	CbGpPWpGaD
Varenicline—Hypersensitivity—Doxorubicin—lung cancer	2.89e-05	0.000158	CcSEcCtD
Varenicline—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	2.88e-05	0.00016	CbGpPWpGaD
Varenicline—Vomiting—Methotrexate—lung cancer	2.88e-05	0.000158	CcSEcCtD
Varenicline—Rash—Methotrexate—lung cancer	2.85e-05	0.000157	CcSEcCtD
Varenicline—Dermatitis—Methotrexate—lung cancer	2.85e-05	0.000156	CcSEcCtD
Varenicline—Headache—Methotrexate—lung cancer	2.84e-05	0.000156	CcSEcCtD
Varenicline—Asthenia—Doxorubicin—lung cancer	2.81e-05	0.000154	CcSEcCtD
Varenicline—CHRNA3—Transmission across Chemical Synapses—HRAS—lung cancer	2.8e-05	0.000156	CbGpPWpGaD
Varenicline—Pruritus—Doxorubicin—lung cancer	2.77e-05	0.000152	CcSEcCtD
Varenicline—Nausea—Methotrexate—lung cancer	2.69e-05	0.000147	CcSEcCtD
Varenicline—Diarrhoea—Doxorubicin—lung cancer	2.68e-05	0.000147	CcSEcCtD
Varenicline—CHRNA7—Transmission across Chemical Synapses—HRAS—lung cancer	2.66e-05	0.000148	CbGpPWpGaD
Varenicline—Dizziness—Doxorubicin—lung cancer	2.59e-05	0.000142	CcSEcCtD
Varenicline—CHRNA4—SIDS Susceptibility Pathways—IL6—lung cancer	2.53e-05	0.000141	CbGpPWpGaD
Varenicline—Vomiting—Doxorubicin—lung cancer	2.49e-05	0.000137	CcSEcCtD
Varenicline—Rash—Doxorubicin—lung cancer	2.47e-05	0.000136	CcSEcCtD
Varenicline—Dermatitis—Doxorubicin—lung cancer	2.47e-05	0.000135	CcSEcCtD
Varenicline—Headache—Doxorubicin—lung cancer	2.46e-05	0.000135	CcSEcCtD
Varenicline—Nausea—Doxorubicin—lung cancer	2.33e-05	0.000128	CcSEcCtD
Varenicline—CHRNA4—Transmission across Chemical Synapses—HRAS—lung cancer	2.16e-05	0.00012	CbGpPWpGaD
Varenicline—CHRNA3—Neuronal System—HRAS—lung cancer	2.14e-05	0.000119	CbGpPWpGaD
Varenicline—CHRNA7—Neuronal System—HRAS—lung cancer	2.03e-05	0.000113	CbGpPWpGaD
Varenicline—CHRNA4—Neuronal System—HRAS—lung cancer	1.66e-05	9.23e-05	CbGpPWpGaD
